CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Income Statement [Abstract]
Net revenues	$ 130,998	$ 133,606	$ 409,411	$ 401,818	$ 535,031
Cost of revenues	29,749	30,206	85,979	85,190	114,877
Gross profit	101,249	103,400	323,432	316,628	420,154
Operating costs and expenses:
Research, development and clinical studies	51,956	48,141	151,265	144,372	201,303
Sales and marketing	41,395	32,580	124,029	98,075	137,057
General and administrative	32,509	31,231	94,683	95,116	126,127
Total operating costs and expenses	125,860	111,952	369,977	337,563	464,487
Operating income (loss)	(24,611)	(8,552)	(46,545)	(20,935)	(44,333)
Financial expenses (income), net	(1,194)	1,981	2,743	5,567	7,742
Income (loss) before income tax	(23,417)	(10,533)	(49,288)	(26,502)	(52,075)
Income tax	3,159	2,591	5,943	5,391	6,276
Net income (loss)	$ (26,576)	$ (13,124)	$ (55,231)	$ (31,893)	$ (58,351)
Basic net income (loss) per ordinary share (in usd per share)	$ (0.25)	$ (0.13)	$ (0.53)	$ (0.31)	$ (0.56)
Weighted average number of ordinary shares used in computing basic net income (loss) per share (in shares)	104,884,583	103,731,147	104,552,803	103,281,380	103,433,274
Diluted net income (loss) per ordinary share (in usd per share)	$ (0.25)	$ (0.13)	$ (0.53)	$ (0.31)	$ (0.56)
Weighted average number of ordinary shares used in computing diluted net income (loss) per share (in shares)	104,884,583	103,731,147	104,552,803	103,281,380	103,433,274